KRAS and neoplasm: It is noteworthy that KRASG12D protein was clearly evident in the fractions of one patient from each group, suggesting that the isolated EVs specific to PDAC tumour cells, as > 80% of PDAC patients contain mutated KRAS and of which 28% patients carry KRAS point mutation (G>A) [19].